Mauna Kea Technologies SA (MKEAF)
| Previous close | 0.3700 |
| Open | 0.3700 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.3700 - 0.3700 |
| 52-week range | 0.3700 - 0.4200 |
| Volume | |
| Avg. volume | 177 |
| Market cap | 26.51M |
| Beta (5Y monthly) | 1.38 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0600 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Mauna Kea Technologies: Publication of the 2023 Annual Financial Report
PARIS & BOSTON, April 30, 2024--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT) (Paris:ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that it has published its Annual Financial Report for the year ended 31 December 2023 and filed it with the Autorité des Marchés Financiers (AMF) on 30 April 2024.
- Business Wire
Mauna Kea Technologies Announces the Opening of a French Center of Excellence for the Use of Cellvizio® in Lung Cancer Diagnostics
PARIS & BOSTON, April 29, 2024--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT) (Paris:ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced the opening of a French Center of Excellence for the use of Cellvizio in lung cancer diagnostics. The Cellvizio procedure is now performed preoperatively by Prof. Stéphane Renaud, MD, PhD, a leading thoracic surgeon at the University Hospital (CHRU) in N
- Business Wire
Mauna Kea Technologies Reports Full Year 2023 Results and Q1 2024 Sales
PARIS & BOSTON, April 25, 2024--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today reported its financial results for the full year 2023 and its sales for the first quarter 2024.
